Announced details
Overall response rate for E7386: 36.7% (11 patients)
Overall response rate among patients with no prior treatment with LENVIMA®: 57.1%
Target of conducting high-throughput screening at a scale of 10 programs per year
5 programs launched and 4 hit compounds obtained in the first half of fiscal 2026
5 programs were launched and 4 hit compounds were obtained in the first half of fiscal 2026 (as of 13 June 2026).
Radio NIKKEI is the seminar organizer. The Company has licensing, joint research or joint development relationships with Eisai, 大原薬品工業, Ono Pharmaceutical, Roche, Genentech and Merck, among others. The Company collaborates with Talus Bio and Receptor AI to build drug discovery platforms.
Radio NIKKEI is the event organizer. The other parties are described in the materials in part as pharmaceutical companies, global companies and drug discovery biotechs, but no detailed company profiles are provided.
PepMetics® is a registered trademark of the Company. The clinical trial identifiers listed are NCT03833700, NCT04008797, NCT05091346, NCT03264664, NCT03620474, jRCT2031230195 and NCT06144086.
Shonan iPark, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Nihonbashi Life Science Building 2, 3-11-5 Nihonbashi-Honcho, Chuo-ku, Tokyo
For E7386, the total value, including upfront payments, development and sales milestones, and research funding, is at least ¥25 billion. Royalties have not been disclosed. PRI-724: not disclosed. Other agreements: not disclosed.
For the interim accounting period of the fiscal year ending September 2026, net sales were ¥253 million, operating loss was ¥584 million, ordinary loss was ¥560 million and net loss was ¥603 million. No impact on business performance from the release of the seminar materials itself is stated.
The company does not address Offering price.
jRCT
ClinicalTrials.gov
European Society for Medical Oncology（ESMO）Congress 2025
Protein Data Bank Japan (PDB)
Datamonitor Healthcare
Pharma Intelligence（EvaluatePharma）
Literature review and publicly available industry information
| Item | Details |
|---|---|
| Names of Products / Services Covered | PepMetics® technology, E7386, PRI-724（OP-724、Foscenvivint） |
| Counterparty | Radio NIKKEI, エーザイ, 大原薬品工業, Ono Pharmaceutical Co., Ltd., Roche, Genentech, Merck, Talus Bio, Receptor AI |
| Counterparty overview | Radio NIKKEI is the event organizer. The other parties are described in the materials in part as pharmaceutical companies, global companies and drug discovery biotechs, but no detailed company profiles are provided. |
| Relationship with the Company | Radio NIKKEI is the seminar organizer. The Company has licensing, joint research or joint development relationships with Eisai, 大原薬品工業, Ono Pharmaceutical, Roche, Genentech and Merck, among others. The Company collaborates with Talus Bio and Receptor AI to build drug discovery platforms. |
| Contract Value | For E7386, the total value, including upfront payments, development and sales milestones, and research funding, is at least ¥25 billion. Royalties have not been disclosed. PRI-724: not disclosed. Other agreements: not disclosed. |
| Contract Date | Seminar date: 13 June 2026. The months and years in which the existing agreements were signed are April 2011 for E7386, May 2018 for PRI-724, April 2024 for Ono Pharmaceutical, December 2021 for Roche and Genentech, October 2020 for Merck, December 2025 for Talus Bio, and March 2026 for Receptor AI. |
| Applicable area | Cancer, Fibrosis, Cirrhosis, Endometrial cancer, Kinases, Membrane proteins, Protein-protein interaction (PPI) drug discovery |
| Registration number and expiry date | PepMetics® is a registered trademark of the Company. The clinical trial identifiers listed are NCT03833700, NCT04008797, NCT05091346, NCT03264664, NCT03620474, jRCT2031230195 and NCT06144086. |
| Location | Shonan iPark, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Nihonbashi Life Science Building 2, 3-11-5 Nihonbashi-Honcho, Chuo-ku, Tokyo |
| Location scale | 40 employees. |
| Quantitative Effects | Overall response rate for E7386: 36.7% (11 patients), Overall response rate among patients with no prior treatment with LENVIMA®: 57.1%, Target of conducting high-throughput screening at a scale of 10 programs per year, 5 programs launched and 4 hit compounds obtained in the first half of fiscal 2026 |
| Usage history | 5 programs were launched and 4 hit compounds were obtained in the first half of fiscal 2026 (as of 13 June 2026). |
| Impact on Business Performance | For the interim accounting period of the fiscal year ending September 2026, net sales were ¥253 million, operating loss was ¥584 million, ordinary loss was ¥560 million and net loss was ¥603 million. No impact on business performance from the release of the seminar materials itself is stated. |
| Source | jRCT, ClinicalTrials.gov, European Society for Medical Oncology（ESMO）Congress 2025, Protein Data Bank Japan (PDB), Datamonitor Healthcare, Pharma Intelligence（EvaluatePharma）, Literature review and publicly available industry information |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To give investors broad access to the materials and deepen their understanding of the Company. The Company also aims to promote dialogue with shareholders and investors and advance its IR activities to enhance corporate value.